What is the Amicus Therapeutics Inc. stock price forecast?

Amicus Therapeutics Inc. is currently trading at $208.80. View real-time AI analysis on Alpha Lenz.

What is Amicus Therapeutics Inc. insider trading activity?

View the latest insider trading data for Amicus Therapeutics Inc. on Alpha Lenz.

What is Amicus Therapeutics Inc.'s P/E ratio?

View Amicus Therapeutics Inc.'s valuation metrics on Alpha Lenz.

Amicus Therapeutics Inc.

NASDAQ · FOLD

$208.80+0.00(+0.00%)Pre-market

Ask about Amicus Therapeutics Inc.'s future dividend policy...

Alpha Chat Insight

“Amicus Therapeutics Inc.'s ROE is -11.6%. Explore profitability and growth together.”

Ask for details →

Company Overview

Amicus Therapeutics Inc. is a biopharmaceutical company dedicated to developing advanced therapies for rare and orphan diseases. Its primary focus is on genetic disorders, particularly lysosomal storage disorders and other diseases resulting from improper protein folding within cells. Amicus leverages its proprietary technology platforms to create drug candidates that address unmet medical needs, providing innovative solutions for complex conditions like Fabry disease and Pompe disease. The company's commitment to patient-centric innovation aims to enhance the quality of life for individuals facing challenging health diagnoses. Situated within the biotechnology sector, Amicus plays a significant role in advancing novel treatment options, thereby impacting healthcare markets and potentially transforming the standard of care for rare genetic diseases. Founded in 2002, the company harnesses cutting-edge research and collaborations to foster groundbreaking developments in the therapeutic landscape uniquely shaped by the complexities of rare diseases.

CEOMr. Bradley L. Campbell M.B.A.

Websitehttps://amicusrx.com

SectorHealthcare

IndustryBiotechnology

Employees499

Company Statistics

FY 2025

Profile

N/AMarket Cap

$634.21MRevenue

0.00Shares Out

499Employees

Margins

88.50%Gross

8.75%EBITDA

5.44%Operating

0.03%Pre-Tax

-4.27%Net

Valuation

N/AP/E

N/AP/B

N/AEV/Sales

N/AEV/EBITDA

N/AP/FCF

Growth (CAGR)

24.43%Rev 3Yr

19.44%Rev 5Yr

N/AOp Inc 3Yr

N/AOp Inc 5Yr

N/ANet Inc 3Yr

N/ANet Inc 5Yr

Returns

-3.13%ROA

-11.58%ROE

5.34%ROIC

Financial Health

$214.01MCash & Cash Equivalents

$461.62MNet Debt

246.36%Debt/Equity

N/AInterest Cov

Alpha Chat Insight

“Amicus Therapeutics Inc.'s ROE is -11.6%. Explore profitability and growth together.”

Ask for details →

Frequently Asked Questions

Amicus Therapeutics Inc. (ticker: FOLD) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 499 employees.

The current price is $208.8 with a P/E ratio of -x and P/B of -x.

ROE is -11.58% and operating margin is 5.44%. Annual revenue is $634M.